Showing 441 - 460 results of 1,779 for search '(( 10 (((peter OR per) decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( 5 10 decrease ))*', query time: 0.31s Refine Results
  1. 441
  2. 442

    Role of pharmacist in cardiovascular disease-related health promotion and in hypertension and dyslipidemia management: A cross-sectional study in the State of Qatar by El Hajj, Maguy Saffouh

    Published 2016
    “…More than 70% responded with rarely or never to 6 out of the 10 CVD health promotion activities. Eighty-four per cent and 68% always or often describe to patients the appropriate time to take antihypertensive medications and the common medication adverse effects, respectively. …”
    Get full text
    Get full text
  3. 443
  4. 444

    A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries by Mason, Helen

    Published 2014
    “…Cumulative population health effects were quantified as life years gained (LYG) over a 10 year time frame. The costs of each policy were estimated using evidence from comparable policies and expert opinion including public sector costs and costs to the food industry. …”
    Get full text
    Get full text
  5. 445
  6. 446
  7. 447
  8. 448
  9. 449
  10. 450
  11. 451
  12. 452
  13. 453
  14. 454
  15. 455

    Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021 by Sirota, Sarah Brooke

    Published 2024
    “…From 2019 to 2021, the global all-age incidence rate fell by 0·5% (–0·8 to –0·1). Globally, the incidence rate of URIs was 162 484·8 per 100 000 population (144 834·0 to 183 289·4) in 2021, a decrease of 10·5% (–12·4 to –8·4) from 1990, when the incidence rate was 181 552·5 per 100 000 population (160 827·4 to 206 214·7). …”
    Get full text
    Get full text
    Get full text
    article
  16. 456
  17. 457
  18. 458
  19. 459

    Efficacy of a novel topical fipronil, (S)-methoprene, eprinomectin and praziquantel combination against naturally acquired intestinal nematode and cestode infections in cats by Knaus, Martin

    Published 2014
    “…In each study, cats were assigned randomlyto blocks of two animals each, based on decreasing pre-treatment body weight and wererandomly allocated to one of two groups of six to 12 cats: untreated (control) or treatedwith topical fipronil (8.3%, w/v), (S)-methoprene (10%, w/v), eprinomectin (0.4%, w/v)and praziquantel (8.3%, w/v) (BROADLINE®, Merial) at 0.12 mL/kg body weight (providinga minimum of 10 mg fipronil + 12 mg S-methoprene + 0.5 mg eprinomectin + 10 mg prazi-quantel per kg body weight). …”
    Get full text
    Get full text
  20. 460